$ZEAL News
Last published 2d ago
- 2d agoZEALZealand Pharma to participate in the Jefferies Global Healthcare ConferenceGlobeNewswirePress release – No. 23 / 2026
- 2d agoZEALZealand Pharma to participate in the Jefferies Global Healthcare ConferenceGlobeNewswirePress release – No. 23 / 2026 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, November 9, 2026 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology
- 2d agoZEALZealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardiometabolic benefitsGlobeNewswireCompany announcement – No. 55 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3
- 2d agoZEALZealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardiometabolic benefitsGlobeNewswireCompany announcement – No. 55 / 2026
- 6d agoZEALZealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial resultsGlobeNewswirePress Release – No. 22 / 2026 Zealand Pharma conference call on Nov 12 at 2pm CET (8am ET) to present third quarter 2026 financial results Copenhagen, Denmark, November 5, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL)
- 3w agoZEALZealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830GlobeNewswirePress release – No. 21 / 2026 Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 ZP9830 is a novel Kv1.3 ion channel blocker
- 4w agoZEALGENBZealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesGlobeNewswirePress release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine
- 4w agoGENBZEALGenerate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesGlobeNewswireCollaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will
- 1mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 38, 2026)GlobeNewswireCompany announcement No. 49 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) Copenhagen, Denmark, September 21, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 1mo agoZEALZealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndromeGlobeNewswirePress release – No. 16 / 2026 Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome The CHMP of the European Medicines Agency has recommended the
- 1mo agoZEALMorgan Stanley 24th Annual Global Healthcare Conference - ZEALAND PHARMA AEarnings Call TranscriptsCool. Well, thank you all for being here. I'm James Machen from the Morgan Stanley Banking team and delighted to have Adam from Zeeland Pharma here this morning. I guess over the next 30, 35 minutes, we'll dive into a nu
- 1mo agoZEALElvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 DiabetesBusiness WireThe company plans to advance the licensed GLP-1/gastrin dual-agonist peptide portfolio from Zealand Pharma as a disease-modifying therapy to regenerate and protect endogenous beta-cell mass in patients with type 1
- 1mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 37, 2026)GlobeNewswireCompany announcement No. 48 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) Copenhagen, Denmark, September 14, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 2mo agoZEALZealand Pharma increases its share capital as a result of the exercise of employee warrantsGlobeNewswireCompany announcement – No. 47 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, September 10, 2026 – Zealand Pharma A/S ("Zealand Pharma")
- 2mo agoZEALZealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewswirePress release – No. 15 / 2026 Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference Copenhagen, Denmark, September 9, 2026 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078),
- 2mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 36, 2026)GlobeNewswireCompany announcement No. 46 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) Copenhagen, Denmark, September 7, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 2mo agoZEALCorrection: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)GlobeNewswireCompany announcement No. 45 / 2026 Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, September 2, 2026 – Zealand Pharma A/S ("the Company" or
- 2mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 35, 2026)GlobeNewswireCompany announcement No. 44 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, August 31, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 2mo agoZEALTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsGlobeNewswireCompany announcement – No. 43 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark,
- 2mo agoZEALZealand Pharma – Notification of holding of treasury sharesGlobeNewswireCompany announcement – No. 42 / 2026 Zealand Pharma – Notification of holding of treasury shares Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma")
- 2mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 34, 2026)GlobeNewswireCompany announcement No. 41 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 34, 2026) Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 2mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 33, 2026)GlobeNewswireCompany announcement No. 40 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 33, 2026) Copenhagen, Denmark, August 17, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 3mo agoZEALZealand Pharma Announces Financial Results for the First Half of 2026GlobeNewswireCompany announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum
- 3mo agoZEALRPRXZealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertideGlobeNewswireCompany announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100
- 3mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 32, 2026)GlobeNewswireCompany announcement No. 37 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Copenhagen, Denmark, August 10, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 3mo agoZEALZealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial resultsGlobeNewswirePress Release – No. 14 / 2026 Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results Copenhagen, Denmark, August 6, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL)
- 3mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 31, 2026)GlobeNewswireCompany announcement No. 36 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 31, 2026) Copenhagen, Denmark, August 3, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 3mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 30, 2026)GlobeNewswireCompany announcement No. 35 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 30, 2026) Copenhagen, Denmark, July 27, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 3mo agoZEALTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsGlobeNewswireCompany announcement – No. 34 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, July
- 3mo agoZEALZealand Pharma: Transactions related to share buy-back program (week 29, 2026)GlobeNewswireCompany announcement No. 33 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 29, 2026) Copenhagen, Denmark, July 20, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 4mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 28, 2026)GlobeNewswireCompany announcement No. 32 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 28, 2026) Copenhagen, Denmark, July 13, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 4mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 27, 2026)GlobeNewswireCompany announcement No. 31 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 27, 2026) Copenhagen, Denmark, July 6, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 4mo agoZEALTotal number of shares and voting rights in Zealand Pharma as of June 30, 2026GlobeNewswireCompany announcement – No. 30 / 2026 Total number of shares and voting rights in Zealand Pharma as of June 30, 2026 Copenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S ("Zealand Pharma" or "the
- 4mo agoZEALZealand Pharma major shareholder announcement: The Capital Group Companies, Inc.GlobeNewswireCompany announcement No. 29 / 2026 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 4mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 26, 2026)GlobeNewswireCompany announcement No. 28 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 26, 2026) Copenhagen, Denmark, June 29, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 4mo agoZEALTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsGlobeNewswireCompany announcement – No. 27 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, June
- 4mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 25, 2026)GlobeNewswireCompany announcement No. 26 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 25, 2026) Copenhagen, Denmark, June 22, 2026 – Zealand Pharma A/S ("the Company" or "Zealand
- 4mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 24, 2026)GlobeNewswireCompany announcement No. 25 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 24, 2026) Copenhagen, Denmark, June 15, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma")
- 5mo agoZEALTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsGlobeNewswireCompany announcement – No. 24 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, June
- 5mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 23, 2026)GlobeNewswireCompany announcement No. 23 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 23, 2026) Copenhagen, Denmark, June 8, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma")
- 5mo agoZEALZealand Pharma increases its share capital as a result of the exercise of employee warrantsGlobeNewswireCompany announcement – No. 22 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 8, 2026 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL)
- 5mo agoZEALZealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysisGlobeNewswireCompany announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in
- 5mo agoZEALNew data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesityGlobeNewswirePress release – No. 13 / 2026 New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience
- 5mo agoZEALJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - ZEALAND PHARMA AEarnings Call TranscriptsBrilliant. Thank you all for coming. Today, I'm joined by the Zeeland team, both Henriette, CFO, as well as Upal for the CSO. We've got a Q&A lined up that we'll jump straight into. But I mean, I think what's perhaps mos
- 5mo agoZEALZealand Pharma to participate in the Goldman Sachs Global Healthcare ConferenceGlobeNewswirePress release – No. 12 / 2026 Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference Copenhagen, Denmark, June 2, 2026 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology
- 5mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 22, 2026)GlobeNewswireCompany announcement No. 20 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 22, 2026) Copenhagen, Denmark, June 1, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma")
- 5mo agoZEALTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsGlobeNewswireCompany announcement – No. 19 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May
- 5mo agoZEALZealand Pharma to participate in the Jefferies Global Healthcare ConferenceGlobeNewswirePress release – No. 11 / 2026 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, May 27, 2026 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company
- 5mo agoZEALZealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific SessionsGlobeNewswirePress release – No. 10 / 2026 Zealand Pharma to Present Data atthe American Diabetes Association's 2026 Scientific Sessions Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater
- 5mo agoZEALZealand Pharma - Transactions related to share buy-back program (week 21, 2026)GlobeNewswireCompany announcement No. 18 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 21, 2026) Copenhagen, Denmark, May 26, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma")